top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Mechanism of Action:
TG2 Inhibitor
Duration of Study
~35 Weeks
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Asvini Kulasingham, RRT
bottom of page